Late preterm infants (LPIs) represent a distinct neonatal population at risk for respiratory complications. Respiratory distress syndrome (RDS) remains a common cause of morbidity in this group. The reviewed article focuses on the role of surfactant therapy in LPIs, summarizing available evidence about prevention, pathophysiology, clinical indications, timing, and modes of administration.
The authors emphasize that despite the clinical importance of RDS in LPIs, there is a notable lack of standardized guidance specific to this gestational-age group. Clinical practice regarding when and how to deliver surfactant to LPIs varies substantially among practitioners.
Reported incidence rates of RDS in the late preterm population vary across studies, with figures ranging from 8% to 30.6%. This variability likely reflects differences in study populations, diagnostic criteria, local practice patterns, and definitions applied in individual reports. The range underlines that RDS is a meaningful clinical problem in LPIs, but the precise burden can differ by setting.
The review discusses the current understanding of RDS pathophysiology as it pertains to LPIs. LPIs occupy an intermediate developmental stage in pulmonary maturation; surfactant production and lung structural development may be insufficient compared with term infants, increasing vulnerability to alveolar collapse and impaired gas exchange. The source indicates that this pathophysiologic context informs considerations about preventive measures and the potential role for therapeutic surfactant, though detailed mechanistic or quantitative data are not presented in the abstract.
Antenatal corticosteroids are evaluated in the review as a preventive strategy for RDS in LPIs. The authors summarize current evidence regarding the role of antenatal steroids in reducing the incidence or severity of RDS in this gestational window. The abstract notes that the review covers this topic but does not report specific effect sizes or guideline-level recommendations; readers are referred to the full text for detailed data and analysis.
The review highlights that clinical criteria used to decide which LPIs receive surfactant are highly variable. Common drivers of surfactant administration in neonatal practice—such as progressive oxygen requirement, radiographic findings, or need for respiratory support—are likely relevant, but the abstract states that no universally accepted set of criteria for LPIs exists. Specific thresholds, standardized scoring systems, or decision algorithms for surfactant in LPIs are not delineated in the abstract and would require review of the full article.
Surfactant therapy is described as time-sensitive, with outcomes often dependent on prompt recognition and treatment of surfactant deficiency. However, among clinicians there is no clear consensus on the optimal timing for surfactant administration in LPIs. The review examines existing perspectives and evidence on timing, but the abstract does not provide definitive timing recommendations; it instead underscores ongoing uncertainty and heterogeneity in practice.
Mode of administration is another area of variability. The review considers different delivery approaches for surfactant in LPIs and summarizes available evidence about their use. The abstract does not list specific modes (for example, endotracheal instillation versus less invasive techniques) or comparative outcomes. Therefore, concrete recommendations on preferred delivery method for LPIs are not provided in the abstract and require consultation of the full review for details.
Across the topics covered—prevention with antenatal steroids, pathophysiology, clinical criteria for treatment, timing, and mode of administration—the review identifies substantial heterogeneity in clinical practice and incomplete consensus. Key gaps highlighted include the absence of widely accepted, evidence-based guidelines tailored to LPIs and the need for clearer, standardized clinical criteria to guide surfactant therapy. Where the abstract lacks specific data (for example, precise thresholds, dosing, or comparative outcome measures), it explicitly indicates that those details are not reported there and would be found only in the full text.
In summary, RDS affects a meaningful proportion of LPIs (reported incidence 8%–30.6%), but management strategies—particularly regarding surfactant therapy—are inconsistent. Antenatal steroids are addressed as a preventive measure, and the physiologic basis for surfactant use in LPIs is reviewed. The literature reviewed by the authors points to time-sensitive benefits of surfactant but also to a lack of consensus on clinical triggers, timing, and delivery technique in late preterm infants. Clinicians caring for LPIs should be aware of this variability and the current evidence gaps; the review calls for clearer guidance and further research targeted to this gestational subgroup. Specific procedural or dosing recommendations, comparative outcomes, and guideline statements were not detailed in the abstract and require review of the full article for actionable directives.